Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition

NCT03111810 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Iatrogenic Cushing's Disease

Interventions

DRUG: AZD4017 and prednisolone
DRUG: Placebo Oral Tablet and prednisolone

Sponsor

University of Oxford

Collaborators

[object Object]